US FDA makes changes to improve operations at cancer drug review office
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has renamed and reorganised its office responsible for reviewing drug and biologic applications for cancer therapies, in a bid to boost how the office operates1.